AbbVie and Roche’s blood cancer drug Venclexta just nabbed an FDA approval that spares certain relapsed leukemia patients chemotherapy—and could be key to $3 billion in peak sales to boot. More: AbbVie, Roche drive Venclexta toward B with Rituxan combo
read moreLast week, vocal investors called for Allergan CEO and Chairman Brent Saunders to give up one of those titles, making room for an outsider at the top. But sources say the outsider some shareholders have in mind is actually a
read moreA number of AbbVie products coming out of its North Chicago, Illinois, manufacturing facility have been tied to death complaints, including its mammoth blockbuster Humira, and the FDA says the drugmaker has not done enough to investigate those complaints. More:
read moreChina’s WuXi Biologics, which is trying to rapidly establish itself as a biologics CDMO with global reach, says it will build a manufacturing operation in the U.S. More: WuXi Biologics to build U.S. plant as it rapidly moves beyond its
read moreIn the brand-new tardive dyskinesia market, doctors initially preferred Neurocrine’s Ingrezza over Teva’s Austedo. But that edge is weakening, one analyst says. More: Doctors are coming around to Teva's Austedo as TD drugs get more play: analyst Source: fierce
read moreThe University of Huddersfield has launched the Centre for Pharmaceutical Policy and Practice Research, tasked with keeping the industry “armed with the latest research methods and advice”. More: Huddersfield Uni launches pharma policy and practice research centre Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals